Gastric Balloon for Weight Loss: The Evidence vs GLP-1s, ESG, and Surgery

An intragastric balloon (gastric balloon, marketed as Orbera, ReShape, Obalon, or Spatz3) is a soft silicone balloon placed inside the stomach and inflated to take up space, so you feel full on less food. It is the most temporary of the weight-loss procedures: the balloon stays in for about 6 months and is then removed, and meaningful weight regain after removal is common. In the pooled data behind FDA approval, the Orbera balloon produced roughly 25.4% excess weight loss and about 11.3% total body weight loss (TBWL) at 12 months — peaking near 13.2% TBWL at 6 months while the balloon is in place — across 17 studies and 1,683 patients^[1]. That clears the medical-society adoption bar^[1][3], and a large meta-analysis found real metabolic benefits^[2]. But honestly framed, the balloon delivers less weight loss than a GLP-1 (semaglutide ~14.9%^[4]; tirzepatide ~20.9%^[5]), less than endoscopic sleeve gastroplasty (~13.6%^[6]), it lasts only 6 months, and it carries a real FDA safety signal including death reports^[7]. This article covers what the balloon is, how much weight it takes off and for how long, the FDA safety history in full, cost, and who it actually suits.

The honest summary

• The gastric balloon works — modestly, and only while it is in. The pooled Orbera data (ASGE PIVI meta-analysis^[1]) show about 25.4% excess weight loss and ~11.3% TBWL at 12 months, with the peak (~13.2% TBWL) at 6 months while the balloon is indwelling. Typical real-world results land around 7–15% TBWL.
• It is a temporary, 6-month device. The balloon is placed, left for about 6 months, then endoscopically removed. Weight regain after removal is common, because nothing about your anatomy or the underlying biology has been permanently changed.
• It clears the medical-society adoption bar. Endoscopic bariatric therapies were held to the ASGE/ASMBS “PIVI” thresholds — at least 25% excess weight loss and at least 5% more TBWL than control — and the Orbera balloon meets them^[1][3].
• It improves metabolic markers. A large meta-analysis (Popov 2017^[2]) of 10 randomized trials plus 30 observational studies (5,668 subjects) found improved fasting glucose, waist circumference, and blood pressure, with a type-2-diabetes-resolution odds ratio around 1.4.
• But it delivers less than a GLP-1 or ESG. The balloon (~7–15% TBWL) sits below semaglutide (~14.9%^[4]), well below tirzepatide (~20.9%^[5]), and below ESG (~13.6%^[6]) — and, unlike those, its effect is capped at 6 months.
• There is a genuine FDA safety signal, including deaths. The FDA issued Letters to Health Care Providers in February 2017, August 2017, June 2018, and April 2020; as of those reports 18 deaths worldwide had been reported since Orbera and ReShape were approved in 2015, including 8 in the U.S.^[7] Named risks include gastric perforation, acute pancreatitis, and spontaneous hyperinflation.
• It is a niche tool, not a first-line answer. For most people comparing options, a GLP-1 or ESG is the stronger choice; the balloon's honest niche is a short-term jump-start — see our gastric balloon vs GLP-1 head-to-head.

What a gastric balloon actually is

A gastric balloon is a soft, expandable device that sits inside the stomach and physically occupies volume, so the stomach fills faster and empties more slowly — you eat less and feel full sooner. It is a form of bariatric endoscopy: no incisions, no cutting or stapling, and no permanent change to the anatomy. Most balloons are placed endoscopically under light sedation in about 20–30 minutes; at least one type is swallowed as a capsule. After roughly 6 months the balloon is deflated and removed endoscopically. The main marketed devices differ in the details:

• Orbera — a single silicone balloon placed endoscopically and filled with saline (typically ~400–700 mL); the device behind most of the pooled efficacy data^[1].
• ReShape (Integrated Dual Balloon) — a saline-filled dual-balloon design, also endoscopically placed and removed; approved alongside Orbera in 2015^[7].
• Obalon — a gas-filled balloon system swallowed as a capsule (up to three balloons placed over time), inflated with a mix of gases rather than liquid.
• Spatz3 — an adjustable saline balloon whose volume can be increased or decreased during the treatment period to manage tolerance or plateau.

How much weight does a gastric balloon take off?

The best pooled evidence comes from the ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis (Abu Dayyeh 2015^[1]), which examined the endoscopic therapies against the ASGE “PIVI” adoption thresholds. For the Orbera balloon, pooling 17 studies and 1,683 patients:

• ~25.4% excess weight loss at 12 months — clearing the PIVI bar of at least 25% excess weight loss^[1].
• ~11.3% total body weight loss (TBWL) at 12 months, and about 13.2% TBWL at 6 months — the peak, reached while the balloon is still in place^[1].
• More than 5% additional TBWL over control, satisfying the second PIVI threshold for adopting an endoscopic bariatric therapy^[1][3].

Notice the shape of that curve: weight loss peaks at 6 months and then partly reverses as the balloon comes out and appetite returns. That is the single most important thing to understand about a balloon — the number you see quoted is a peak, not a plateau. In practice, clinicians describe typical results in the range of 7–15% TBWL, with the durable, kept-off figure lower once regain is accounted for. The balloon does not alter anatomy the way a surgical or endoscopic sleeve does, so once it is removed, keeping the weight off depends entirely on sustained behavior change.

The metabolic benefit is real

Weight is not the only outcome. The largest synthesis of the balloon's metabolic effects is Popov 2017 (Am J Gastroenterol^[2]), which pooled 10 randomized controlled trials and 30 observational studies covering 5,668 subjects. Compared with controls, intragastric balloon therapy improved fasting glucose, waist circumference, and blood pressure, and was associated with a type-2-diabetes-resolution odds ratio of roughly 1.4. The same analysis put the serious adverse-event rate around 1.3% in the studied populations. So the balloon does more than move the scale — it shifts cardiometabolic risk factors in the right direction while it is in place. The open question is durability: those gains, like the weight loss, are tied to a device that comes out at 6 months.

The FDA safety history — stated carefully

This is the part of the balloon story that gets glossed over in clinic brochures, and it deserves to be stated accurately because it is a genuine safety matter. Between 2017 and 2020 the FDA issued four Letters to Health Care Providers about liquid-filled intragastric balloons — in February 2017, August 2017, June 2018, and April 2020^[7]. The key facts, taken directly from those communications:

• Deaths. As of those reports, 18 deaths worldwide had been reported since the Orbera and ReShape balloons were FDA-approved in 2015, including 8 in the United States (5 associated with Orbera and 3 with ReShape)^[7]. The FDA noted it could not always establish a definitive causal link, but reported the numbers so clinicians and patients could weigh them.
• Gastric perforation. Tearing of the stomach wall was among the serious complications reported, some requiring emergency intervention^[7].
• Acute pancreatitis. The balloon can compress nearby gastrointestinal structures and trigger acute pancreatitis — in some reported cases as early as 3 days after placement^[7].
• Spontaneous hyperinflation. The balloon can over-fill on its own with additional air or fluid, causing pain, swelling, and intolerance and requiring premature removal of the device^[7].

How the balloon compares (cross-trial, not head-to-head)

Most people researching a balloon are really comparing it against a GLP-1, ESG, and surgery. No trial has pitted these against each other directly, so the table below is a cross-trial comparison — directional, not a contest. The pattern is clear: the balloon is the least durable and generally the lowest-magnitude of the options.

• The balloon is the shortest-acting option on the list. Its effect is capped at the 6-month device life; a GLP-1 keeps working as long as you take it^[4][5], and ESG's restriction lasts years^[6].
• It is also the lowest-magnitude for most people. Even at its 6-month peak, the balloon lands at or below the drugs and ESG, and after regain the kept-off number is lower still^[1].
• It is the only option on the list with FDA death reports attached. That does not make it unusable, but it changes the risk conversation^[7].
• Where it can shine is speed and simplicity. It is a one-time, ~20-minute placement with no daily or weekly medication — a defensible short-term jump-start before or alongside a longer-term plan.

For the full drug-versus-device argument, see our dedicated gastric balloon vs GLP-1 comparison and the broader endoscopic weight-loss options overview.

Prefer a GLP-1 to a temporary device? Top vetted providers

Cost and insurance

In the United States a gastric balloon is typically quoted at roughly $6,000–$9,000 and is usually paid entirely out of pocket, because most insurers classify it as investigational and do not cover it. That is a large one-time cost for a 6-month device — and once you factor in the regain that commonly follows removal, the cost-per-kept-off-pound can be unfavorable versus alternatives. A GLP-1 costs money every month but keeps working while you take it; ESG is a bigger one-time cost but lasts years. Run the numbers over a realistic horizon — see how much weight-loss surgery costs and what insurance covers. (The $6,000–$9,000 figure is a current US market range, not a trial-derived number.)

Who is a gastric balloon actually for?

• People who want a short-term jump-start — for example, to build early momentum, kick off a lifestyle program, or lose weight ahead of another procedure — and who understand the effect ends when the balloon comes out^[1].
• People who cannot take, tolerate, or afford a GLP-1 long-term and want a non-drug, one-time intervention for a defined period.
• People with lower-grade obesity who want a procedural nudge without altering their anatomy and without the higher magnitude (or higher commitment) of ESG or surgery.
• People who will pair it with real behavior change — because the balloon's biggest weakness is regain, the plan for after removal matters more than the balloon itself.

Who it is not ideal for: anyone seeking durable, larger weight loss (ESG, a GLP-1, or surgery will serve better), and anyone for whom the FDA-reported risks are unacceptable given a lower-risk alternative exists^[7].

What we still don't know

• No head-to-head balloon-vs-GLP-1 trial exists. Every drug-vs-device comparison here is cross-trial and should be read as directional.
• Durable, real-world kept-off weight after removal is under-characterized. The headline numbers are 6- and 12-month figures around a device that comes out; long-term regain trajectories vary widely.
• The optimal balloon-plus-medication sequence is unsettled. Using a balloon as a jump-start and a GLP-1 for maintenance is plausible but not established in large trials.
• Device generation matters. Most safety data and death reports involve the liquid-filled balloons; newer and gas-filled designs may carry different risk profiles that are still being characterized^[7].

Bottom line

• A gastric balloon produces roughly 25% excess weight loss and ~11–13% TBWL over its 6-month lifespan^[1] and improves metabolic markers^[2] — but the effect is temporary and regain after removal is common.
• It is the least durable and generally lowest-magnitude of the endoscopic and GLP-1 options: below semaglutide^[4], well below tirzepatide^[5], and below ESG^[6].
• It carries a documented FDA safety signal, including 18 death reports worldwide (8 in the U.S.), plus perforation, acute pancreatitis, and spontaneous hyperinflation^[7] — a risk conversation a GLP-1 does not require in the same form.
• It is usually paid out of pocket (~$6,000–$9,000) for a 6-month device.
• Its honest niche is a short-term jump-start; for durable results most people are better served by a GLP-1, ESG, or surgery — see the balloon vs GLP-1 head-to-head.

Related research

• Gastric balloon vs GLP-1 — the head-to-head on weight loss, durability, safety, and cost
• Endoscopic sleeve gastroplasty (ESG): the evidence — the more durable incisionless procedure
• Endoscopic weight-loss options — balloons, ESG, and the rest of bariatric endoscopy
• ESG vs GLP-1 (semaglutide, tirzepatide) — procedure vs drug at a higher weight-loss tier
• ESG vs surgical gastric sleeve — incisionless vs surgical stomach reduction
• What is the safest form of weight-loss surgery? — procedural risk compared
• How much is weight-loss surgery? — the cost picture the balloon competes in
• Does insurance cover weight-loss surgery? — why the balloon is usually out of pocket
• How much does a gastric balloon cost? — the ~$6,000–$9,000 out-of-pocket price and why the value case is weak

Important disclaimer. This article is educational and does not constitute medical advice. An intragastric balloon is an invasive device with real risks, including the FDA-reported deaths, gastric perforation, acute pancreatitis, and spontaneous hyperinflation described above; suitability depends on your BMI, health, and goals and must be assessed by a qualified bariatric endoscopist or obesity-medicine physician. Cross-trial comparisons with GLP-1 drugs, ESG, and surgery are not head-to-head and should be interpreted with care. Cost figures are current US market ranges, not trial-derived. Do not start, stop, or change any treatment based on this article; if you have a balloon and develop severe abdominal or back pain, vomiting, or trouble breathing, seek urgent care. PMIDs were independently verified against the PubMed E-utilities API on 2026-07-01, and the FDA safety facts were verified against fda.gov.

Last verified: 2026-07-01. Next review: every 12 months, or sooner if the FDA issues a new balloon safety communication or a head-to-head balloon-vs-GLP-1 trial is published.